The availability of genetically modified mice has advanced our understanding of Alzheimer's disease (AD). Nevertheless, conventional tools of cellular neurobiology, which require the sacrifice of an animal to obtain information about neuronal function, preclude the use of longitudinal study designs. Functional Magnetic Resonance Imaging (fMRI) is a technology that can obtain information about the metabolic state of the brain non-invasively and thus allows the use of longitudinal study designs in both rodents and humans. Some fMRI protocols, such as those designed to measure cerebral blood volume (CBV), are especially sensitive to long term metabolic changes in the brain caused by neurodegenerative disease. Mounting evidence suggests that calcium-binding proteins (CaBPs) play a role in Alzheimer's disease (AD). In this proposal, the technologies of fMRI and transgenic engineering will be combined to accomplish the following primary goals: First, to acquire expertise in mouse fMRI as it specifically applies to AD research. Second, to rely on mouse fMRI to investigate the role calcium-binding proteins play in AD pathophysiology. ? This goal will be achieved by crossing mouse models of AD with transgenic mice in whom calcium-binding proteins have been manipulated, and then by imaging these mice prospectively over time. As a secondary goal, in vitro techniques will be used to confirm and extend the in vivo findings. These experiments will test the specific single cell calcium abnormalities in different cellular compartments of the hippocampal formation. The training aspects of this proposal will lead to a new investigator in the field of AD research with combined expertise in clinical neurology and mouse fMRI. The scientific aspects of this proposal will test a specific mechanism regarding AD pathophysiology, which might inform future therapeutic goals. It is also important to emphasize that advances in mouse fMRI can be easily applied to humans, e.g. evaluation of the response to a given treatment by brain fMRI parameters. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08AG027476-02
Application #
7281288
Study Section
National Institute on Aging Initial Review Group (NIA)
Program Officer
Snyder, Stephen D
Project Start
2006-09-01
Project End
2011-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
2
Fiscal Year
2007
Total Cost
$137,317
Indirect Cost
Name
Suny Downstate Medical Center
Department
Neurology
Type
Schools of Medicine
DUNS #
040796328
City
Brooklyn
State
NY
Country
United States
Zip Code
11203
Moreno, H; Morfini, G; Buitrago, L et al. (2016) Tau pathology-mediated presynaptic dysfunction. Neuroscience 325:30-8
Wöhr, M; Orduz, D; Gregory, P et al. (2015) Lack of parvalbumin in mice leads to behavioral deficits relevant to all human autism core symptoms and related neural morphofunctional abnormalities. Transl Psychiatry 5:e525
Sandoval-Hernández, Adrián G; Buitrago, Luna; Moreno, Herman et al. (2015) Role of Liver X Receptor in AD Pathophysiology. PLoS One 10:e0145467
Cepeda-Prado, Efrain; Popp, Susanna; Khan, Usman et al. (2012) R6/2 Huntington's disease mice develop early and progressive abnormal brain metabolism and seizures. J Neurosci 32:6456-67
Moreno, Herman; Burghardt, Nesha S; Vela-Duarte, Daniel et al. (2012) The absence of the calcium-buffering protein calbindin is associated with faster age-related decline in hippocampal metabolism. Hippocampus 22:1107-20
Qiang, Liang; Fujita, Ryousuke; Yamashita, Toru et al. (2011) Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons. Cell 146:359-71
Moreno, Herman; Yu, Eunah; Pigino, Gustavo et al. (2009) Synaptic transmission block by presynaptic injection of oligomeric amyloid beta. Proc Natl Acad Sci U S A 106:5901-6
Moreno, Herman; Wu, William E; Lee, Thomas et al. (2007) Imaging the Abeta-related neurotoxicity of Alzheimer disease. Arch Neurol 64:1467-77